Cirujano General

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Cirujano General >Year 2018, Issue 2

Ocampo GS, Sanz MA, Santiago NF, López AP, Jiménez PL
Short term results of bariatric surgery in the Civil Hospital of Guadalajara Fray Antonio Alcalde
Cir Gen 2018; 40 (2)

Language: Español
References: 29
Page: 94-104
PDF: 227.90 Kb.

Full text


Introduction: Bariatric surgery is the best method for obesity control and its comorbidities, unfortunately there are few studies in the Mexican population. Objective: To evaluate the effect at 12 months of bariatric surgery in the control of obesity and its associated comorbid diseases. Methods: A prospective cohort study was conducted in patients of the Hospital Civil of Guadalajara Fray Antonio Alcalde in which 124 morbidly obese patients underwent gastric bypass and 36 underwent sleeve gastrectomy were included. They were evaluated before surgery and at 3, 6 and 12 months postoperative. The following variables were assessed: weight, body mass index, glycemia, liver and kidney function, dyslipidemia, blood pressure, frequency of cases of sleep apnea and osteo-articular alterations. Results: The initial average weight in patients with gastric bypass was 46.7 ± 8 kg/m2 and decreased to 28.8 ± 8 kg/m2 12 months after surgery and in the sleeve gastrectomy from 128.57 kg/m2 to 89.20 kg/m2. 45 patients undergoing BPGYR had type 2 diabetes, and at 12 months only one persisted. In the group of sleeve gastrectomy initially nine were diabetic and in the end none. At 12 months after surgery, improvement in liver and kidney function was observed, dyslipidemias, arterial hypertension, sleep apnea and osteoarticular alterations in both groups decreased. Conclusions: Our study points to, that bariatric surgery is a short term, effective treatment for morbid obesity and its associated diseases in the Mexican population.

Key words: Bariatric surgery, gastric bypass by Roux Y, vertical sleeve gastrectomy, morbid obesity, body mass index, type 2 diabetes, dyslipidemia, arterial hypertension, hepatic function, renal function.


  1. Bartrina JA, Pérez RC. Epidemiología de la obesidad mórbida. En: Rubio-Herrera MA, Ballesteros-Pomar MD. Manual de obesidad mórbida. Cap. 1, 2a ed. Buenos Aires: Ed. Med. Panamericana; 2015. p. 3-12.

  2. Barquera S, Campos I, Hernández L, Pedroza TA. Prevalencia de obesidad en adultos mexicanos. En: Hernández-Ávila M, Rivera-Dommarco J, Shamah-Levy T, Cuevas-Nasu L, cols. ENSANUT 2016. Instituto Nacional de Salud Publica Mex; 2016. pp. 64-73.

  3. Gutiérrez Guerrero Guadalupe, IMSS, Jalisco, Delegación de Salud Pública; 2010.

  4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.

  5. American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care. 2017; 40: S57-S63.

  6. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes–5-year outcomes. N Engl J Med. 2017; 376: 641-651.

  7. Rosenthal RJ, Szomstein S, Kennedy CI, Soto FC, Zundel N. Laparoscopic surgery for morbid obesity: 1,001 consecutive bariatric operations performed at the bariatric institute, Cleveland Clinic Florida. Obes Surg. 2006; 16: 119-124.

  8. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014; 149: 275-287.

  9. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357: 753-761.

  10. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724-1737.

  11. Nowak JZ. Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids. Postepy Hig Med Dosw (Online). 2010; 64: 115-132.

  12. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880.

  13. Morinigo R, Casamitjana R, Delgado S, Lacy A, Deulofeu R, Conget I, et al. Insulin resistance, inflammation, and the metabolic syndrome following Rouxen-Y gastric bypass surgery in severely obese subjects. Diabetes Care. 2007; 30: 1906-1098.

  14. Pantoja MJ. La ciencia detrás de la cirugía bariátrica. Cir Gen. 2010; 32: 27-29.

  15. Ionut V, Bergman RN. Mechanisms responsible for excess weight loss after bariatric surgery. J Diabetes Sci Technol. 2011; 5: 1263-1282.

  16. Ortiz-Dominguez ME. NORMA Oficial Mexicana NOM-008-SSA3-2010, Para el tratamiento integral del sobrepeso y la obesidad. SEGOB. Diario Oficial de la Federación. 04/08/2010.

  17. Buchwald H, Buchwald JN, McGlennon TW. Systematic review and meta-analysis of medium-term outcomes after banded Roux-en-Y gastric bypass. Obes Surg. 2014; 24: 1536-1551.

  18. Kang JH, Le QA. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017; 96: 46: e8632.

  19. Puzziferri N, Roshek TB 3rd, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery. A siystematic review. JAMA. 2014; 312: 934-942.

  20. Peterli R, Wölnerhanssen BK, Vetter D, Nett P, Gass M, Borbély Y et al. Laparoscopic sleeve gastrectomy versus Roux-Y-gastric bypass for morbid obesity -3-year outcomes of the prospective randomized Swiss multicenter bypass or sleeve study (SM-BOSS). Ann Surg. 2017; 265: 466-473.

  21. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at three years after bariatric surgery among patients with severe obesity. JAMA. 2013; 310: 2416-2425.

  22. Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012; 9: 590-598.

  23. Leonetti F, Capoccia D, Coccia F, Casella G, Baglio G, Paradiso F, et al. Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs medical treatment. Arch Surg. 2012; 147: 694-700.

  24. Leslie DB, Dorman RB, Serrot FJ, Swan TW, Kellogg TA, Torres-Villalobos G, et al. Efficacy of the Roux-en-Y gastric bypass compared
to medically managed controls in meeting the american diabetes association composite end point goals
for management of type 2 diabetes mellitus. Obes Surg. 2012;22:367-374.

  25. Li J, Lai D, Wu D. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy to treat morbid obesity-related comorbidities: a systematic review and meta-analysis. Obes Surg. 2016; 26: 429-442.

  26. Ooi GJ, Earnest A, Doyle L, Laurie Ch, John M, Wentworth JM, et al. Detailed description of change in serum cholesterol profile with incremental weight loss after restrictive bariatric surger. Obes Surg. 2018; 28: 1351-1362. (https://doi.org/10.1007/s11695-017-3015-9).

  27. Ooi GJ, Burton PR, Doyle L, Wentworth JM, Bhathal PS, Sikaris K, et al. Effects of bariatric surgery on liver function tests in patients with nonalcoholic fatty liver disease. Obes Surg. 2017; 27: 1533-1542.

  28. Dixon JB. Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease. Clin Liver Dis. 2014; 18: 129-146.

  29. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013; 2013: 839275.

>Journals >Cirujano General >Year 2018, Issue 2

· Journal Index 
· Links 

Copyright 2019